Literature DB >> 25616460

Standard dose valproic acid does not cause additional cognitive impact in a rodent model of intractable epilepsy.

Adam P Jellett1, Kyle Jenks2, Marcella Lucas2, Rod C Scott3.   

Abstract

Children with epilepsy face significant cognitive and behavioral impairments. These impairments are due to a poorly characterized interaction between the underlying etiology, the effect of seizures and the effect of medication. The large variation in these factors make understanding the main drivers of cognitive impairment in humans extremely difficult. Therefore, we investigated the cognitive effect of seizures and the antiepileptic drug valproic acid in a rodent model of cortical dysplasia. Rats were divided into seizure-receiving and non-receiving groups. Rats experienced frequent early life seizures using the flurothyl inhalation method: 50 seizures between postnatal day 5 and 15 and then one seizure a day following that. Rats were further divided into drug-treated and vehicle treated groups. Valproic acid treated animals were treated from 5 days preceding behavioral testing in the Morris water maze at a clinically relevant concentration. We show here that the main driver of cognitive impairments are the brain malformations, and that persistent seizures in animals with brain malformations and valproic acid caused no additional impact. These findings suggest that neither an appropriate dose of a standard antiepileptic drug or intractable seizures worsen cognition associated with a malformation of cortical development and that alternative treatment strategies to improve cognition are required.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hippocampus; Methylazoxymethanol acetate; Pediatric epilepsy; Valproic acid

Mesh:

Substances:

Year:  2014        PMID: 25616460      PMCID: PMC4397905          DOI: 10.1016/j.eplepsyres.2014.11.005

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  18 in total

1.  Chronic antiepileptic toxicity: a review.

Authors:  E H Reynolds
Journal:  Epilepsia       Date:  1975-06       Impact factor: 5.864

2.  Impaired cognition in rats with cortical dysplasia: additional impact of early-life seizures.

Authors:  Marcella M Lucas; Pierre-Pascal Lenck-Santini; Gregory L Holmes; Rod C Scott
Journal:  Brain       Date:  2011-05-20       Impact factor: 13.501

3.  Early identification of refractory epilepsy.

Authors:  P Kwan; M J Brodie
Journal:  N Engl J Med       Date:  2000-02-03       Impact factor: 91.245

4.  Clinical and imaging features of cortical malformations in childhood.

Authors:  R J Leventer; E M Phelan; L T Coleman; M J Kean; G D Jackson; A S Harvey
Journal:  Neurology       Date:  1999-09-11       Impact factor: 9.910

5.  Effects of antiepileptic drugs on induced epileptiform activity in a rat model of dysplasia.

Authors:  Matthew D Smyth; Nicholas M Barbaro; Scott C Baraban
Journal:  Epilepsy Res       Date:  2002-08       Impact factor: 3.045

Review 6.  Comorbidities in pediatric epilepsy: beyond "just'' treating the seizures.

Authors:  L D Hamiwka; E C Wirrell
Journal:  J Child Neurol       Date:  2009-04-08       Impact factor: 1.987

7.  Phenobarbital modifies seizure-related brain injury in the developing brain.

Authors:  M A Mikati; G L Holmes; A Chronopoulos; P Hyde; S Thurber; A Gatt; Z Liu; S Werner; C E Stafstrom
Journal:  Ann Neurol       Date:  1994-09       Impact factor: 10.422

Review 8.  Treatment of pediatric epilepsy: European expert opinion, 2007.

Authors:  James W Wheless; Dave F Clarke; Alexis Arzimanoglou; Daniel Carpenter
Journal:  Epileptic Disord       Date:  2007-12       Impact factor: 1.819

9.  Traumatic brain injury in the developing rat: effects of maturation on Morris water maze acquisition.

Authors:  M L Prins; D A Hovda
Journal:  J Neurotrauma       Date:  1998-10       Impact factor: 5.269

Review 10.  Malformations of cortical development and epilepsy.

Authors:  Richard J Leventer; Renzo Guerrini; William B Dobyns
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.